Norwood, MA United States
Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company’s lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in clinical studies in systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.
[stock_market_widget type=”chart” symbol=”CRBP” chart=”line” range=”1y” interval=”1mo” line-color=”rgb(49, 125, 189)”]
Newton, MA United States
MariMed Inc. provides consulting services for the design, development, operation, funding, and optimization of medical cannabis cultivation, production, and dispensary facilities. The company also develops and manages facilities for the cultivation, production, and dispensing of legal cannabis and cannabis-infused products under the Kalm Fusion brand name. In addition, it offers legal, accounting, human resources, and other corporate and administrative services. As of December 31, 2017, it developed and managed six operating cannabis facilities for clients in Delaware, Illinois, Nevada, and Maryland. MariMed Inc. was incorporated in 2011 and is based in Newton, Massachusetts.
[stock_market_widget type=”chart” symbol=”MRMD” chart=”line” range=”1y” interval=”1mo” line-color=”rgb(49, 125, 189)”]
9th Floor 107 Elm Street
Stamford, CT United States
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with chronic kidney disease associated pruritus undergoing hemodialysis, as well as in Phase II/III clinical trial for the treatment of dialysis patients suffering from uremic pruritus. The company is also developing Oral KORSUVA (CR845/difelikefalin) that has completed Phase I clinical trial to treat uremic pruritus; and in Phase I clinical trial to treat pruritus chronic kidney disease, as well as in Phase I clinical trial for treating pruritus chronic liver disease. In addition, it is developing CR845/difelikefalin Injection, which is in Phase III clinical trial for the treatment of acute post-operative pain; and Oral CR845/difelikefalin that has completed Phase IIb for treating chronic pain, as well as CR701, which is in preclinical trial for the treatment of chronic pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.
[stock_market_widget type=”chart” symbol=”CARA” chart=”line” range=”1y” interval=”1mo” line-color=”rgb(49, 125, 189)”]
New York, NY United States
iAnthus Capital Holdings, Inc. engages in the delivery of solutions for financing, developing, and managing state-licensed cannabis cultivators and dispensaries in the United States. The company is headquartered in New York, New York.
[stock_market_widget type=”chart” symbol=”ITHUF” chart=”line” range=”1y” interval=”1mo” line-color=”rgb(49, 125, 189)”]
HONEYSUCKLE is a print and digital publication that emphasizes diverse voices and visual impact. Each quarter, our print edition explores a topical issue through a range of perspectives. Our intimate style of reporting combines input from high-profile celebrities, leaders in various fields, and personal testimony. Online, we expand the conversation in daily posts that include journalism, first-person essays, reviews and poetry. Our cross-generational audience is open, inclusive, and curious, united by their shared passion for knowledge and desire to dive deep into important themes that shape our time.
To date, our print editions have covered topics such as women’s roles and rights, home and homelessness, cannabis as a growing and politically charged industry, and the evolution of sex in our culture. Our covers have featured Oscar nominee Kirsten Dunst, iconic activist actor Alan Cumming, bi-racial model/rapper and homelessness activist Justin Bullock. Major features include Oscar winner Holly Hunter, NFL legend and cannabis advocate/entrepreneur Marvin Washington; Bruce Giffin, acclaimed photojournalist from Detroit, and more. High-quality color printing enables us to refract our topics through photography, painting, and illustration, bringing vibrancy to each page.
National print distribution, inclusion in industry gift bags at events such as New York Fashion Week and SXSW, and a thriving online presence enable HONEYSUCKLE to reach a richly varied audience. Unlike many publications, we do not adapt our material to a given demographic. Rather, we assume that our readers’ interests are broad, and that cross-cultural and cross-generational exchange is vital. In an age of polarity, we seek to soften boundaries and spread information that creates respectful dialogue and action. In as much as human lives are defined by what we care about, we bring that passion to our pages.
Topics we plan to discuss are Sustainability, Quantum Thinking and Social issues.
“Founded by filmmaker Ronit Pinto, Honeysuckle is devoted to expression through all forms of media and offers a unique approach to video storytelling. Through our in-house production company Black Neon Media (staffed by professionals who have worked with Wes Craven, Michael Bay, and Steven Spielberg), as well as collaborations with other dynamic collectives, we produce original content that is at once entertaining, informative, and provocative. In film we aim to push the artistic envelope while composing thoughtful and engaging narratives which center on themes including sexuality, spirituality, violence, activism, and technological innovation.”
Williamsville, NY United States
22nd Century Group, Inc., a plant biotechnology company, provides technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding. It offers premium cigarettes under the RED SUN and MAGIC brands; and SPECTRUM, a line of research cigarettes for use in independent clinical studies. The company’s products under development include BRAND A, a very low nicotine cigarette; X-22, a tobacco-based botanical medical product for use as an aid to smoking cessation; and BRAND B, a low-tar-to-nicotine ratio cigarette. In addition, it engages in contract manufacturing business for third-party branded tobacco products. The company has scientific collaborations with the University of Virginia and Anandia Laboratories, Inc. to develop proprietary hemp strains with less than 0.3% dry weight content of delta-9-tetrahydrocannabinol. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Williamsville, New York.
[stock_market_widget type=”chart” symbol=”XXII” chart=”line” range=”1y” interval=”1mo” line-color=”rgb(49, 125, 189)”]
Suite 8, Level 2 57 Shenton Avenue
Joondalup, WA Australia
AusCann Group Holdings Ltd researches, develops, cultivates, produces, and sells clinically validated cannabis medicines to patients in Australia. The company has a strategic partnership with Tasmanian Alkaloids Pty Ltd. AusCann Group Holdings Ltd is based in Joondalup, Australia.
[stock_market_widget type=”chart” symbol=”ACNNF” chart=”line” range=”1y” interval=”1mo” line-color=”rgb(49, 125, 189)”]
Chandler, AZ United States
Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It is also developing Cannabidiol Oral Solution, which has completed pediatric study for the treatment of pediatric epilepsy; has completed Phase II study to treat west syndrome; and is in Phase II study for the treatment of childhood absence epilepsy, as well as Buprenorphine Sublingual Spray that has completed Phase III study to treat acute pain. In addition, the company is developing Cannabidiol Oral Solution for the treatment of prader willi; Buprenorphine/Naloxone Sublingual Spray to treat opioid dependence; and Naloxone Nasal Spray for the treatment of opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.
[stock_market_widget type=”chart” symbol=”INSY” chart=”line” range=”1y” interval=”1mo” line-color=”rgb(49, 125, 189)”]
Poway, CA United States
Medical Marijuana, Inc., an investment holding company, operates in the medical marijuana and industrial hemp markets. Its products range from patented and proprietary based cannabinoid products to seed and stalk or isolated high value extracts manufactured and formulated for the pharmaceutical, nutraceutical, and cosmeceutical industries. The company licenses its proprietary testing, genetics, labeling and packaging, tracking, production, and standardization methods for the medicinal cannabinoid industry. It engages in the research and development of cannabinoid-based pharmaceuticals; and marketing and distribution of cannabidiol hemp oil-based products. In addition, the company provides management support and services to cooperatives, collectives, health and wellness facilities, and medical clinics; and consulting and securities services to businesses and individuals in the legal cannabis industry. Further, it focuses on the treatment of pain and other medical disorders with the application of chewing gum-based cannabis/cannabinoid medical products. Medical Marijuana, Inc. was formerly known as Hemp Deposit Distribution Corp. and changed its name to Medical Marijuana, Inc. in March, 2011. The company was incorporated in 2003 and is headquartered in Poway, California.
[stock_market_widget type=”chart” symbol=”MJNA” chart=”line” range=”1y” interval=”1mo” line-color=”rgb(49, 125, 189)”]
Irvine, CA United States
Terra Tech Corp. operates as a vertically integrated cannabis-focused agriculture company. The company operates in two segments, Herbs and Produce Products; and Cannabis Dispensary, Cultivation and Production. The Herbs and Produce Products segment offers hydroponic herbs, produce, and floral products. The Cannabis Dispensary, Cultivation and Production segment operates medical marijuana retail and adult use dispensaries under the name Blüm, which provides a selection of medical and adult use cannabis products, such as flowers, concentrates, and edibles; and produces and sells a line of medical and adult use cannabis flowers, as well as a line of medical and adult use cannabis-extracted products comprising concentrates, cartridges, vape pens, and wax products in California and Nevada. Terra Tech Corp. was founded in 2010 and is headquartered in Irvine, California.
[stock_market_widget type=”chart” symbol=”TRTC” chart=”line” range=”1y” interval=”1mo” line-color=”rgb(49, 125, 189)”]